Results 161 to 170 of about 79,311 (270)

Homoisoflavanone Delays Colorectal Cancer Progression via DNA Damage‐Induced Mitochondrial Apoptosis and Parthanatos‐Like Cell Death

Advanced Science, Volume 13, Issue 19, 2 April 2026.
Homoisoflavanone (HIF), a bioactive compound isolated from Polygonatum kingianum, selectively suppresses colorectal cancer progression by inducing DNA damage‐mediated mitochondrial apoptosis and parthanatos‐like cell death. HIF triggers mitochondrial dysfunction, including depolarized membrane potential, elevated ROS, and ATP depletion, while impairing
Hongjie Fan, Huzi Zhao, Pei Zhang, Pengfei Yu, Yunfei Ji, Gang Chen, Hongli Jin, Yanfang Liu, Jin Liu, Zhe‐Sheng Chen, Aiping Lyu, Xinmiao Liang, Yang Chen   +12 more
wiley   +1 more source

Survival of patients with colorectal or pancreatic cancer who received <i>UGT1A1</i> genotype-guided dosing of irinotecan in the Netherlands (2017-2024): a retrospective, multicentre cohort study. [PDF]

Lancet Reg Health Eur
Peeters SLJ, Heersche N, Böhm D, Böhringer S, Guiljam R, Hulshof EC, de Man FM, de With M, Joosse M, Oomens G, Wu QY, Osman A, Bins S, van Hellemond IEG, Haberkorn BCM, Verschoor AJ, Wumkes ML, van Schaik RHN, Thijs AM, Gelderblom H, Guchelaar HJ, Mathijssen RHJ, Deenen MJ.   +22 more
europepmc   +1 more source

Polyphenol‐Based Biomaterials Against Cancer Radio/Chemotherapy‐Induced Intestinal Toxicity

Advanced NanoBiomed Research, Volume 6, Issue 4, April 2026.
Radiotherapy/chemotherapy often causes intestinal toxicity, impairing cancer patients’ quality of life and treatment efficacy. Polyphenols protect against this injury via multiple mechanisms, but face oral use limitations. This review outlines their protective mechanisms and delivery challenges, highlighting recent oral delivery advances and future ...
Jixu Lu, Jing Chen, Ji Zhu, Lixin Ru, Dongxiao Zhang   +4 more
wiley   +1 more source

Cost-effectiveness of switching to S-1 after fluoropyrimidine-induced hand-foot syndrome or cardiovascular toxicity in the treatment of metastatic colorectal cancer. [PDF]

ESMO Open
van Eekelen R, Punt CJA, Kwakman JJM, Coupé VMH.   +3 more
europepmc   +1 more source

Multi‐omics Analysis Reveals the Correlation of Gut Microbiota and Metabolites With Thalidomide Treatment for Chemotherapy‐Induced Nausea and Vomiting in Small Cell Lung Cancer

Biotechnology Journal, Volume 21, Issue 4, April 2026.
Graphical Abstract and Lay Summary We characterize the gut microbiota signatures associated with Thalidomide treatment in small cell lung cancer patients experiencing chemotherapy‐induced nausea and vomiting. The analysis reveals significant changes in specific genera, linking microbial composition to symptom management. ABSTRACT Small cell lung cancer
Qiang‐Guo Sun, Dan Zang, Yu Xin, Jia Cui, Xu Han, Jun Chen   +5 more
wiley   +1 more source

NALIRIFOX versus liposomal irinotecan plus fluorouracil/leucovorin as the second-line chemotherapy in gemcitabine refractory pancreatic adenocarcinoma: a real-world study. [PDF]

Ther Adv Med Oncol
Wong WZ, Chiang NJ, Lee KC, Yu HY, Tsai CJ, Hsu SJ, Lee PC, Chen MH, Huang HC, Li CP, Luo JC, Lee FY.   +11 more
europepmc   +1 more source

Combining Small‐Molecular Compounds With CAR T‐Cell Therapy: Novel Strategies for Enhanced Cancer Immunotherapy

Cancer Innovation, Volume 5, Issue 2, April 2026.
Chimeric antigen receptor (CAR) T‐cell therapy, although revolutionary for haematological malignancies, faces significant challenges, including T‐cell exhaustion, limited persistence, and treatment‐related toxicity. The integration of small‐molecule compounds offers a promising strategy to overcome these limitations.
Rangzi Yi, Zijian Zhang, Yang Yang, Haichuan Zhu   +3 more
wiley   +1 more source

Annual Review of Systemic Medical Treatment for Colorectal Cancer in 2025

Cancer Innovation, Volume 5, Issue 2, April 2026.
Tissue biopsy and molecular profilingenable precise patient stratification into distinct molecular subtypes, which guides the selection of precision treatment. Furthermore, longitudinal liquid biopsies facilitate serial ctDNA monitoring for MRD detection and continuous surveillance.
Zengzhi Cai, Fan Chen, Ying Jin, Feng Wang   +3 more
wiley   +1 more source

Phase II study of FOLFIRI with low-dose irinotecan plus ramucirumab as second-line treatment in Japanese patients with metastatic colorectal cancer (study rindo). [PDF]

Jpn J Clin Oncol
Hattori N, Nakayama G, Umeda S, Kishida T, Takeda S, Ezaka K, Tsutsuyama M, Sakai M, Hattori M, Ito T, Kanda M, Tanaka C, Murotani K, Ando M, Kodera Y.   +14 more
europepmc   +1 more source

Progression‐Free Survival 2 as a Potential Surrogate for Overall Survival in Glioblastoma: Insights From a Spanish Multicentric Cohort

Cancer Medicine, Volume 15, Issue 4, April 2026.
Overall, PFS2 correlated more strongly with OS than PFS (0.83 vs. 0.69). PFS2 outperformed PFS in patients with targetable alterations and in those without. Our findings support using PFS2 as a candidate surrogate endpoint in glioblastoma trials. Implementing PFS2 balances trial feasibility with clinical relevance of outcomes.
Jesús Yaringaño, Oriol Mirallas, Víctor Navarro, Diego Gómez‐Puerto, Gabriel Velilla, María Ángeles Vaz, Teresa Gorria, Álvaro Martínez‐Monino, Ainhoa Hernández, María Aguado, Antonio Di Muzio, Daniel López Valbuena, Fiorella Ruiz‐Pace, Macarena González, María Martínez‐García, Guillermo Villacampa, Carmen Balaña, Joan Carles, Rodrigo Dienstmann, Estela Pineda, Juan Manuel Sepúlveda, María Vieito   +21 more
wiley   +1 more source